Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

Cymerus MSCs ease CRS after immunotherapy
November 2018
SHARING OPTIONS:

MELBOURNE, Australia—Cynata Therapeutics Limited reported in September that in a preclinical model, its proprietary Cymerus mesenchymal stem cells (MSCs) were able to significantly ease the effects of cytokine release syndrome (CRS), an adverse reaction to cancer immunotherapy such as CAR-T therapy that can be life-threatening. Treatment with Cymerus MSCs led to statistically significant improvements in body temperature and clinical scores compared to control animals.
 
“These results suggest that administering a single dose of Cymerus MSCs before, during or even shortly after cancer immunotherapy treatment may provide significant therapeutic benefit and a straightforward way of limiting adverse CRS reactions,” said Dr. Kilian Kelly, Cynata’s vice president of product development. “We look forward to continuing to explore the benefits of our MSCs in humans through partnerships with companies commercializing cancer immunotherapies, such as CAR-T.”

Back



PAGE UTILITIES


CONTACT US
DDNEWS
1000 N West Street, Suite 1200,
Wilmington, Delaware, 19801
Ph: 888-781-0328 |  Fax: 705-528-0270
 
© Copyright 2020 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.